JPM-MCS issues request for intent letters for other transaction agreement
Through this OTA, the JPM-MCS and the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) aim to accelerate the development of key technology in certain areas of research and to facilitate supporting technology that would enhance the development of therapeutic medical countermeasures (MCM) and to develop MCMs that target biological and toxic materials deemed significant by the department of defense.
They also seek to develop auto-injector delivery devices that military personnel can carry on their person for single drug administration. Candidates for treatments for prophylaxis and for the identification and treatment of radiological and nuclear threats are also sought.
Letters of intent should include consortium names, corporate point of contacts and full contact information. Technical information for any proposed technology or capability should be no longer than 20 pages. Information within this section should include ability to comply with quality assurance efforts, corporate competencies and other relevant information.
All letters should be submitted by Tuesday, Nov. 24, by 11:59 p.m. ET. The main point of contact regarding this announcement is Kristen Kachur at email@example.com.